Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05081037
Other study ID # 2020/3070
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 6, 2021
Est. completion date May 26, 2026

Study information

Verified date January 2023
Source KK Women's and Children's Hospital
Contact Kok Hian Tan, MD
Phone 65 6394 1099
Email tan.kok.hian@singhealth.com.sg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to test the following hypotheses in a randomized controlled trial of post-partum women with a history of gestational diabetes mellitus (GDM) that will be followed up for up to 4 years: 1. Post-partum pregnancy is ideal for behavioural modification and adopting a healthy lifestyle. Using the continous glucose monitoring (CGM) sensor and an exercise tracker will promote self-motivation and awareness by positive reinforcement and behavioural changes to improve diet, control body weight and increase physical activity in this group of post-partum women who are at high risk for developing Type II Diabetes. 2. The use of the continous glycose monitoring (CGM) sensor and exercise tracker will motivate women to modify their dietary food intake and physical activity over time, reducing their cardiovascular risk factors for developing metabolic syndrome by lowering their baseline blood pressure, BMI, reducing their waist circumference and body fat mass, glycaemic levels and fasting lipids within the targeted healthy range. 3. There will be an increase in the quality adjusted life years (QALYs) gained based on improvements in HbA1C and other proximal outcomes at the end of the trial.


Description:

The increased incidence of gestational diabetes mellitus (GDM) resulting from increased insulin resistance has become a major health concern. GDM affects 5-10% of pregnant women in Europe, while the prevalence in Asian populations is significantly higher at approximately 15-20%. There is a need for early postpartum intervention strategies beginning soon after birth, but yet there are limited of such intervention studies conducted in Asia. This is a randomized controlled trial and hospital-based study. A total of 300 post-partum women who attended KK Women's and Children's Hospital (KKH) for antenatal consultation and were diagnosed with GDM using International association of diabetes and pregnancy study groups (IADPSG) guidelines at KKH, with a BMI range from 20-40, and physically fit to participate in moderate intensity walking will be approached for prospective recruitment. These subjects will be followed-up to determine if they will have normal oral glucose tolerance test (OGTT) results at 6 weeks postpartum. If all the inclusion criteria is met, these women will be recruited into the study. The recruited women will be randomly allocated to the intervention or control group. Those placed in the intervention group, which will also be known as the Wearable Care Group, will receive both a continous glucose monitoring (CGM) and an exercise tracker which will be a FitBit watch. Those placed in the control group, which will also be known as the Scheduled Care Group will receive standard medical care. Participants randomized to both the control (Scheduled Care Group) and the intervention group (Wearable Care Group) will be followed up in the specialist outpatient clinics with a total of 7 visits for up to 4 years. Various testing will be carried out at relevant time points. Data will be collected through questionnaires and clinical measurements. The questionnaires include socio-economic factors, a quality of life questionnaire, maternal diet, medical histories, lifestyle factors, health status, and home environment. Bio-physical measurements will be obtained from anthropometric measurements of participants, human biological materials such as blood, are collected from the participants at their follow-up time points with the I-HIPS study upon their consent.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date May 26, 2026
Est. primary completion date May 26, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 45 Years
Eligibility Inclusion Criteria: 1. Women diagnosed antenatally with GDM by IADPSG criteria (15) 2. Normal 6 weeks post-natal OGTT 3. BMI range from 20-40 4. Physically fit to participate in moderate intensity walking Exclusion Criteria: 1. Women with serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days 2. Women who have any other serious chronic disease such as chronic kidney disease and heart disease

Study Design


Intervention

Device:
Wearable Care Group
Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels.

Locations

Country Name City State
Singapore KK Women's and Children's Hospital Singapore

Sponsors (3)

Lead Sponsor Collaborator
KK Women's and Children's Hospital Duke-NUS Graduate Medical School, Singapore Institute for Clinical Sciences

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in quality of life from baseline at 12 months (10-14 months) Quality of life score measured using the EQ-5D-5L instrument Baseline and 12 months (10-14 months) and 36 months (34-38 months)
Other Change in quality of life from baseline at 36 months (34-38 months) Quality of life score measured using the EQ-5D-5L instrument Baseline and 36 months (34-38 months)
Primary Clinically diagnosed Type II Diabetes Mellitus Clinical outcomes of Type II Diabetes Mellitus development determined by oral glucose tolerance test At 6 months (23-26 weeks) from baseline visit
Primary Clinically diagnosed Type II Diabetes Mellitus Clinical outcomes of Type II Diabetes Mellitus development determined by oral glucose tolerance test At 10-14 months from baseline visit
Primary Clinically diagnosed Type II Diabetes Mellitus Clinical outcomes of Type II Diabetes Mellitus development determined by oral glucose tolerance test At 22-26 months from baseline visit
Primary Clinically diagnosed Type II Diabetes Mellitus Clinical outcomes of Type II Diabetes Mellitus development determined by oral glucose tolerance test At 34-38 months from baseline visit
Primary Body mass index at the end of the 6 month intervention period Using weight and height measures At 6 months (23-26 weeks) from baseline
Primary Body fat mass at the end of the 6 month intervention period Measured using the bioelectrical impedance analysis scale At 6 months (23-26 weeks) from baseline
Secondary Change in total energy intake from baseline at 6 months (23-26 weeks) Assess the effect of continous glucose monitoring sensor use on total energy intake calculated using data captured from the 24-Hour recall food diary. Baseline and 6 months (23-26 weeks)
Secondary Change in total energy intake from baseline, 6 months, 12 months, 24 months and 36 months Assess the effect of continous glucose monitoring sensor use on total energy intake captured using data captured from the 24-Hour recall food diary. Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in diet quality from baseline at 6 months (23-26 weeks) Assess the effect of continous glucose monitoring sensor use on diet quality derived using a 24-Hour recall food diary. Baseline and 6 months (23-26 weeks)
Secondary Change in diet quality from baseline, 6 months,12 months, 24 months and 36 months Assess the effect of continous glucose monitoring sensor use on diet quality derived using a 24-Hour recall food diary. Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in physical activity from baseline at 6 months (23-26 weeks) Assess the effect of exercise tracker use on frequency and duration of physical activity using self-reported data from the International Physical Activity Questionnaire (IPAQ) Baseline and 6 months (23-26 weeks)
Secondary Change in physical activity from baseline, 6 months, 12 months, 24 months and 36 months Assess the effect of exercise tracker use on frequency and duration of physical activity using self-reported data from the International Physical Activity Questionnaire (IPAQ) Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in diastolic and systolic blood pressure measures from baseline at 6 months (23-26 weeks) Using diastolic and systolic blood pressure measures Baseline and 6 months (23-26 weeks)
Secondary Change in diastolic and systolic blood pressure measures from baseline, 6 months, 12 months, 24 months and 36 months Using diastolic and systolic blood pressure measures Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in body mass index measures from baseline at 6 months (23-26 weeks) Calculating body mass index using height and weight measures Baseline and 6 months (23-26 weeks)
Secondary Change in body mass index measures from baseline, 6 months, 12 months, 24 months and 36 months Calculating body mass index using height and weight measures Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in waist circumference measures from baseline at 6 months (23-26 weeks) Using waist circumference measures Baseline and 6 months (23-26 weeks)
Secondary Change in waist circumference measures from from baseline, 6 months, 12 months, 24 months and 36 months Using waist circumference measures Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in body fat mass measures from baseline at 6 months (23-26 weeks) Using body fat mass measured using the bioelectrical impedance analysis scale Baseline and 6 months (23-26 weeks)
Secondary Change in body fat mass measures from baseline, 6 months, 12 months, 24 months and 36 months Using body fat mass measured using the bioelectrical impedance analysis scale Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in HbA1c measures from baseline at 6 months (23-26 weeks) Using HbA1c levels measured from blood samples Baseline and 6 months (23-26 weeks)
Secondary Change in HbA1c measures from baseline, 6 months, 12 months, 24 months and 36 months Using HbA1c levels measured from blood samples Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
Secondary Change in fasting lipid profile from baseline at 6 months (23-26 weeks) Using fasting lipid profiles (total cholesterol, Low-density lipoprotein (LDL) cholesterol, High-density lipoprotein (HDL) cholesterol, triglycerides) of blood samples Baseline and 6 months (23-26 weeks)
Secondary Change in fasting lipid profile from baseline, 6 months, 12 months, 24 months and 36 months Using fasting lipid profiles (total cholesterol, Low-density lipoprotein (LDL) cholesterol, High-density lipoprotein (HDL) cholesterol, triglycerides) of blood samples Baseline, 6 months (23-26 weeks), 12 months (10-14 months), 24 months (22-26 months) and 36 months (34-38 months)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03249896 - Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes N/A
Terminated NCT03749889 - Low Carb vs Normal Carb in Pregnancy N/A
Completed NCT03859193 - Education Nutritional Video for Gestational Diabetics N/A
Recruiting NCT05037526 - Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care in Pregnancy Outcomes N/A
Completed NCT06178250 - Placenta, Fetal Liver, Sectional Ductus Venosus Volumes Examined by Three-dimensional Ultrasound in the Second Trimester N/A
Not yet recruiting NCT06310356 - Continuous Glucose Monitoring for Women With Gestational Diabetes N/A
Not yet recruiting NCT06445530 - Nutrition Optimization and Community Upliftment for Postpartum Recovery N/A
Recruiting NCT02590016 - Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial Phase 4
Withdrawn NCT01947699 - Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide Phase 4
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Recruiting NCT03008824 - Micronutrients in Pregnancy as a Risk Factor for Diabetes and Effects on Mother and Baby N/A
Active, not recruiting NCT01340924 - Relationship Between Gestational Diabetes and Type 2 Diabetes
Completed NCT00534105 - Lipid Metabolism in Gestational Diabetes N/A
Recruiting NCT00371306 - Comparison of Glucovance to Insulin for Diabetes During Pregnancy N/A
Completed NCT03388723 - Intergenerational Programming of Diabesity in Offspring of Women With Gestational Diabetes Mellitus
Recruiting NCT04521712 - Postpartum Glycemia in Women at Risk For Persistent Hyperglycemia N/A
Enrolling by invitation NCT03307486 - Gestational Diabetes: a Cohort Study N/A
Active, not recruiting NCT03301792 - Group Versus Traditional Prenatal Care for Diabetes N/A
Enrolling by invitation NCT05603793 - YoUng Adolescents' behaViour, musculoskeletAl heAlth, Growth & Nutrition
Completed NCT03669887 - Lifestyle Modification to Improve Diet in Women With GDM N/A